SciSparc & Clearmind Bolster Psychedelic Patent Portfolio
Ticker: SPRC · Form: 6-K · Filed: Feb 20, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Feb 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, pharmaceuticals, psychedelics, partnership
TL;DR
**SciSparc and Clearmind are expanding their international patent portfolio for next-gen psychedelic compounds.**
AI Summary
On February 20, 2024, SciSparc Ltd. issued a press release announcing that it and Clearmind Medicine Inc. are strengthening their international patent portfolio. The press release, titled "SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds," indicates a focus on psychedelic-based compounds. This filing, a Form 6-K, reports on this development for the month of February 2024.
Why It Matters
This filing indicates SciSparc's continued investment and strategic focus on developing psychedelic-based compounds, which could impact its future drug pipeline and market position.
Risk Assessment
Risk Level: medium — The development of new pharmaceutical compounds, especially in emerging areas like psychedelics, carries inherent regulatory and clinical trial risks.
Key Players & Entities
- SciSparc Ltd. (company) — registrant and issuer of press release
- Clearmind Medicine Inc. (company) — partner in strengthening patent portfolio
- February 20, 2024 (date) — date of press release and report
- 001-38041 (other) — Commission file number
FAQ
What is the purpose of this 6-K filing by SciSparc Ltd.?
This 6-K filing reports on a press release issued by SciSparc Ltd. on February 20, 2024, titled "SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds."
Which companies are involved in strengthening the international patent portfolio mentioned in the press release?
SciSparc Ltd. and Clearmind Medicine Inc. are the companies involved in strengthening the international patent portfolio.
What type of compounds are the focus of the patent portfolio expansion?
The patent portfolio expansion focuses on "Next Generation Classic Psychedelic-Based Compounds."
When was the press release, which is the subject of this 6-K, issued?
The press release was issued on February 20, 2024.
What is SciSparc Ltd.'s Commission file number?
SciSparc Ltd.'s Commission file number is 001-38041.
Filing Stats: 321 words · 1 min read · ~1 pages · Grade level 9.3 · Accepted 2024-02-20 16:27:17
Filing Documents
- ea0200255-6k_scisparc.htm (6-K) — 13KB
- ea0200255ex99-1_scisparc.htm (EX-99.1) — 8KB
- 0001213900-24-015344.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: February 20, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3